Cingulate Inc. Logo

Cingulate Inc.

A clinical-stage biopharma firm developing treatments for ADHD and anxiety.

CING | US

Overview

Corporate Details

ISIN(s):
US17248W1137 (+1 more)
LEI:
Country:
United States of America
Address:
1901 W. 47TH PLACE, 66205 KANSAS CITY

Description

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The company utilizes its proprietary Precision Timed Release (PTR) drug delivery platform, a novel erosion-based technology, to create medications with a true once-daily dosing profile. This platform is designed to provide controlled drug release for entire active-day efficacy. Cingulate's pipeline includes product candidates CTX-1301 and CTX-1302 for the ADHD market, and CTX-2103 for the anxiety market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Cingulate Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cingulate Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cingulate Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.